Orthobond
About Orthobond
Orthobond was founded in 2004 by Gregory Lutz, M.D. and Professor Jeffery Schwartz Ph.D. with the intent of improving the performance and safety of medical implants. The base technology or platform provides the ability to covalently or chemically bind molecules that can impact the performance of implantable medical devices. The Company’s focus has been on the adhesion of antimicrobial molecules and creating a cost efficient and timely manufacturing process. Orthobond customizes partners’ surfaces by matching substrates with specific end group molecules to elicit the desired biological response.YEAR FOUNDED:
2004
LEADERSHIP:
Founder: Gregory Lutz
JOBS:
Please click here for Orthobond job opportunities.
3 articles about Orthobond
-
Orthobond Secures De Novo Classification Grant for First-in-Class Antibacterial Surface Treatment Applied to a Spinal Device
4/8/2024
Orthobond Corporation, a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, announced today that the U.S. Food and Drug Administration (FDA) granted its De Novo marketing request for the use of Ostaguard™, its proprietary antibacterial surface treatment, on a permanent medical device.
-
Orthobond Appoints Frank Cammisa, MD as Chief Medical Officer
12/9/2021
Orthobond announced the appointment of Frank P. Cammisa, MD, as the company’s Chief Medical Officer.
-
Orthobond Appoints New CEO and New President and COO
11/15/2016